Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
This is an old revision of this page, as edited by Allthemilescombined1 (talk | contribs) at 19:19, 11 October 2024 (The FDA approved Hympavzi on October 11, 2024 for Hemophilia A and B patients ages 12 and older without inhibitors.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Marstacimab is an experimental monoclonal antibody intended for the treatment of hemophilia A and B. It is being developed by Pfizer.
Society and culture
Legal status
In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hympavzi, intended for prophylaxis of bleeding episodes in people aged twelve years of age and older, weighing at least 35 kilograms (77 lb), who have severe hemophilia A or B. The applicant for this medicinal product is Pfizer Europe Ma EEIG.
The FDA approved Hympavzi on October 11, 2024 for Hemophilia A and B patients ages 12 and older without inhibitors.
^ "Hympavzi EPAR". European Medicines Agency (EMA). 19 September 2024. Retrieved 21 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). hdl:10665/330896.
External links
Clinical trial number NCT03938792 for "Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B" at ClinicalTrials.gov
